MediciNova Reveals MN-001 Metabolite Boosts Cholesterol Efflux in Macrophages
MediciNova Inc. announced that its drug candidate MN-001's metabolite, MN-002, enhances cholesterol efflux in macrophages, potentially reducing atherosclerosis risk. The findings, published in the Journal of Atherosclerosis and Thrombosis, validate previous clinical studies. MediciNova has completed Phase 2 trial enrollment for MN-001 in hypertriglyceridemia and NAFLD patients, with results expected by summer 2026.
MediciNova Inc. recently announced significant scientific research findings related to its drug candidate MN-001. According to the company, a study conducted in collaboration with a leading Japanese academic team revealed that MN-002, the primary metabolite of MN-001, enhances cholesterol efflux in macrophages by upregulating ABCA1 and ABCG1 transporters. This mechanism is important for Reverse Cholesterol Transport, which helps clear cholesterol from arterial walls and may reduce the risk of atherosclerosis and cardiovascular disease. These mechanistic findings, which were recently published in the Journal of Atherosclerosis and Thrombosis, provide additional scientific validation for the observed lipid profile improvements in prior MN-001 clinical studies. MediciNova has also completed enrollment for its Phase 2 trial of MN-001 in patients with hypertriglyceridemia and NAFLD due to type 2 diabetes, with top-line results expected by summer 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9594169-en) on December 01, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
